Product News

Share this article:
FDA accepted Amgen's Biolgoics License Application (BLS) for denosumab, an investigation drug seeking indication for the treatment and prevention of postmenopausal osteoporosis in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer.  Last July, IMS Health said denosumab had blockbuster potential, and could net sales over $1 billion.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions